• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vaxcyte Inc. (Amendment)

    2/10/23 4:14:55 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    SC 13G/A 1 d429415dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Vaxcyte, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    92243G108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 92243G108    Schedule 13G    Page 1 of 16

     

      1    

      Names of Reporting Persons

     

      The Carlyle Group Inc.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      CO

     


    CUSIP No. 92243G108    Schedule 13G    Page 2 of 16

     

      1    

      Names of Reporting Persons

     

      Carlyle Holdings I GP Inc.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      CO

     


    CUSIP No. 92243G108    Schedule 13G    Page 3 of 16

     

      1    

      Names of Reporting Persons

     

      Carlyle Holdings I GP Sub L.L.C.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 92243G108    Schedule 13G    Page 4 of 16

     

      1    

      Names of Reporting Persons

     

      Carlyle Holdings I L.P.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      PN

     


    CUSIP No. 92243G108    Schedule 13G    Page 5 of 16

     

      1    

      Names of Reporting Persons

     

      CG Subsidiary Holdings L.L.C.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 92243G108    Schedule 13G    Page 6 of 16

     

      1    

      Names of Reporting Persons

     

      TC Group, L.L.C.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 92243G108    Schedule 13G    Page 7 of 16

     

      1    

      Names of Reporting Persons

     

      Carlyle Investment Management L.L.C.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 92243G108    Schedule 13G    Page 8 of 16

     

      1    

      Names of Reporting Persons

     

      Carlyle Genesis UK LLC

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 92243G108    Schedule 13G    Page 9 of 16

     

      1    

      Names of Reporting Persons

     

      Abingworth LLP

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      England and Wales

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      PN

     


    CUSIP No. 92243G108    Schedule 13G    Page 10 of 16

     

      1    

      Names of Reporting Persons

     

      Abingworth Bioventures VI LP

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      England and Wales

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      2,070,724

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      2,070,724

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,070,724

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      2.6%

    12  

      Type of Reporting Person

     

      PN

     


    CUSIP No. 92243G108    Schedule 13G    Page 11 of 16

     

    ITEM 1.

    (a)     Name of Issuer:

    Vaxcyte, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    825 Industrial Road, Suite 300, San Carlos, CA 94070

     

    ITEM 2.

    (a)     Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    The Carlyle Group Inc.

    Carlyle Holdings I GP Inc.

    Carlyle Holdings I GP Sub L.L.C.

    Carlyle Holdings I L.P.

    CG Subsidiary Holdings L.L.C.

    TC Group, L.L.C.

    Carlyle Investment Management L.L.C.

    Carlyle Genesis UK LLC

    Abingworth LLP

    Abingworth Bioventures VI LP

     

      (b)

    Address or Principal Business Office:

    The principal business address of each of Abingworth LLP and Abingworth Bioventures VI LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.

     

      (c)

    Citizenship of each Reporting Person is:

    Each of Abingworth LLP and Abingworth Bioventures VI LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    92243G108


    CUSIP No. 92243G108    Schedule 13G    Page 12 of 16

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2022, based upon 79,372,477 shares of Common Stock outstanding, which includes (i) 79,320,810 shares of Common Stock outstanding as of December 20, 2022, as disclosed in the Issuer’s registration statement on Form S-3 filed with the Securities and Exchange Commission on December 22, 2022 and (ii) 51,667 shares of Common Stock issuable upon exercise of stock options that may be deemed to be beneficially owned by the reporting person and which are exercisable or will be exercisable within 60 days of the date of this filing.

     

    Reporting Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole
    power to
    vote or to
    direct the
    vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole power
    to dispose
    or to direct
    the
    disposition
         Shared
    power to
    dispose or to
    direct the
    disposition
     

    The Carlyle Group Inc.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Carlyle Holdings I GP Inc.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Carlyle Holdings I GP Sub L.L.C.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Carlyle Holdings I L.P.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    CG Subsidiary Holdings L.L.C.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    TC Group, L.L.C.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Carlyle Investment Management L.L.C.

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Carlyle Genesis UK LLC

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Abingworth LLP

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    Abingworth Bioventures VI LP

         2,070,724        2.6 %      0        2,070,724        0        2,070,724  

    The shares of Common Stock reported herein include (i) 2,019,057 shares of Common Stock held of record by Abingworth Bioventures VI LP and (ii) 51,667 shares of Common Stock underlying stock options exercisable within 60 days of the date of this filing that may be deemed to be beneficially owned by Abingworth Bioventures VI LP.    

    The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C.,


    CUSIP No. 92243G108    Schedule 13G    Page 13 of 16

     

    which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VI LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VI LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VI LP, but each disclaims beneficial ownership of such securities.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following:  ☒

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 92243G108    Schedule 13G    Page 14 of 16

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:    February 10, 2023

     

    The Carlyle Group Inc.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Chief Financial Officer
    Carlyle Holdings I GP Inc.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:  

    Managing Director and Chief Financial

    Officer

    Carlyle Holdings I GP Sub L.L.C.
    By: Carlyle Holdings I GP Inc., its sole member
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:  

    Managing Director and Chief Financial

    Officer

    Carlyle Holdings I L.P.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director
    CG Subsidiary Holdings L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director
    TC Group, L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director


    CUSIP No. 92243G108    Schedule 13G    Page 15 of 16

     

    Carlyle Investment Management L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Chief Financial Officer
    Carlyle Genesis UK LLC
    By: Carlyle Investment Management L.L.C., its sole member
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Chief Financial Officer
    Abingworth LLP
    By:   /s/ John Heard
    Name:   John Heard
    Title:   Authorized Signatory
    Abingworth Bioventures VI LP
    By:   /s/ John Heard
    Name:   John Heard
    Title:   Authorized Signatory


    CUSIP No. 92243G108    Schedule 13G    Page 16 of 16

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    24    Power of Attorney.
    99    Joint Filing Agreement.
    Get the next $PCVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    1/7/2026$90.00 → $110.00Buy
    Needham
    9/12/2025$38.00Neutral
    Goldman
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    More analyst ratings

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Vaxcyte with a new price target

    Needham reiterated coverage of Vaxcyte with a rating of Buy and set a new price target of $110.00 from $90.00 previously

    1/7/26 8:03:12 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Vaxcyte with a new price target

    Goldman initiated coverage of Vaxcyte with a rating of Neutral and set a new price target of $38.00

    9/12/25 7:53:21 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vaxcyte

    Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

    4/22/25 7:35:12 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the cons

    2/5/26 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were $632.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte

    2/2/26 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Announces Pricing of $550 Million Public Offering

    SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its commo

    1/29/26 11:33:04 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    SEC Filings

    View All

    SEC Form 8-K filed by Vaxcyte Inc.

    8-K - Vaxcyte, Inc. (0001649094) (Filer)

    2/2/26 4:01:31 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Vaxcyte Inc.

    424B5 - Vaxcyte, Inc. (0001649094) (Filer)

    1/30/26 5:12:46 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Vaxcyte Inc.

    424B5 - Vaxcyte, Inc. (0001649094) (Filer)

    1/29/26 4:01:12 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Pickering Grant gifted 100,000 shares, decreasing direct ownership by 20% to 400,908 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    1/16/26 5:10:28 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CFO Guggenhime Andrew gifted 61,850 shares and received a gift of 61,850 shares, decreasing direct ownership by 50% to 62,459 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    1/16/26 5:09:55 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brandicourt Olivier was granted 1,357 shares, increasing direct ownership by 118% to 2,505 units (SEC Form 4)

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    1/16/26 5:08:29 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    View All

    Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

    Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to Third and Final Stage Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026 Company Establishing Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy, Aligned with Administration's Focus on Strengthening Domestic Biomanufacturing and Representing up to $1 Billion in Manufacturing and Servi

    11/4/25 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

    SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

    5/1/25 8:00:29 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte Appoints John Furey to Board of Directors

    SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

    7/2/24 8:30:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCVX
    Financials

    Live finance-specific insights

    View All

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

    -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

    3/31/25 7:00:00 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

    SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

    3/30/25 5:00:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

    SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

    2/12/25 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 5:46:11 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 2:53:06 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/12/24 10:34:18 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care